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Abstract
To date structure-activity relationship (SAR) studies of the dynorphins (Dyn), endogenous 
peptides for kappa opioid receptors (KOR), have focused almost exclusively on Dyn A with 
minimal studies on Dyn B. While both Dyn A and Dyn B have identical N-terminal sequences, 
their C-terminal sequences differ which could result in differences in pharmacological activity. We 
performed an alanine scan of the non-glycine residues up through residue 11 of Dyn B amide to 
explore the role of these side chains in the activity of Dyn B. The analogs were synthesized by 
fluorenylmethyloxycarbonyl (Fmoc)-based solid phase peptide synthesis and evaluated for their 
opioid receptor affinities and opioid potency and efficacy at KOR. Similar to Dyn A the N-
terminal Tyr1 and Phe4 residues of Dyn B amide are critical for opioid receptor affinity and KOR 
agonist potency. The basic residues Arg6 and Arg7 contribute to the KOR affinity and agonist 
potency of Dyn B amide, while Lys10 contributes to the opioid receptor affinity, but not KOR 
agonist potency, of this peptide. Comparison to the Ala analogs of Dyn A(1-13) suggests that the 
basic residues in the C-terminus of both peptides contribute to KOR binding, but differences in 
their relative positions may contribute to the different pharmacological profiles of Dyn A and Dyn 
B. The other unique C-terminal residues in Dyn B amide also appear to influence the relative 
affinity of this peptide for KOR. This SAR information may be applied in the design of new Dyn 
B analogs that could be useful pharmacological tools.
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Introduction
The dynorphins, like the other mammalian opioid endogenous peptides, are obtained by 
enzymatic cleavage from a precursor protein, prodynorphin.1 Prodynorphin is primarily 
cleaved into four larger opioid peptides, dynorphin (Dyn) A, leumorphin, and α and β-
neoendorphin,2 and leumorphin is further cleaved to yield Dyn B (Figure 1). Dyn A and Dyn 
B were both initially isolated from porcine pituitary by Fischli and Goldstein.3-5 These 
prodynorphin-derived peptides, which are most abundant in the neural lobe of the rat 
pituitary and in the posterior pituitary, are differentially processed in various parts of the 
brain.2
These prodynorphin peptides preferentially interact with kappa opioid receptors (KOR). In 
radioligand binding assays both peptides exhibit subnanomolar to low nanomolar affinity for 
KOR, with Dyn A exhibiting higher KOR affinity than Dyn B (4.7-fold higher in mouse 
brain preparations6 and 46-fold higher for cloned human KOR7). In mouse brain 
preparations, both Dyn A and Dyn B exhibited 9-fold selectivity for KOR vs. mu opioid 
receptors (MOR).6 In the cloned human opioid receptors, Dyn B exhibited 3-fold selectivity 
for KOR vs. MOR compared to Dyn A which exhibited 261-fold selectivity.7 Both peptides 
exhibit subnanomolar to low nanomolar agonist potency in the guinea pig ileum assay,8,9 
and low nanomolar potency in the GTPγS assay at cloned human KOR.7
In contrast, the reported non-opioid effects of the two peptides are markedly different. Dyn 
A produces non-opioid effects10-12 such as hind limb paralysis13,14 and nociceptive 
behavior15 in rodents, effects that are resistant to naloxone but blocked by administration of 
an N-methyl-D-aspartate (NMDA) antagonist.16 Additionally, Dyn A has been reported to 
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produce long lasting allodynia17,18 and hypothermia19 in rats. (Induction of hypothermia is 
thought to be due to a mixture of opioid and non-opioid effects of dynorphins.19) In 
addition, Dyn A causes cytotoxicity in non-neuronal as well as neuronal cells through a 
mechanism resistant to naloxone.20,21 In contrast, Dyn B did not produce nociceptive 
behavior15 or hypothermia19 in rats. Also unlike Dyn A, Dyn B did not produce cytotoxic 
effects in neuronal and non-neuronal cells in vitro.20
Differences have also been reported for membrane interactions of Dyn A and Dyn B in 
model systems such as phospholipid large unilamellar vesicles (LUVs)22 and in live 
mammalian cells.23 In phospholipid LUVs Dyn A produced membrane perturbations and 
induced calcein leakage, possibly by causing transient pore formation. In contrast, Dyn B 
did not cause membrane perturbation or calcein leakage.22 Studies of the membrane 
interactions of Dyn A and Dyn B with phospholipid bicelles by NMR and saturation transfer 
difference (STD) experiments24 showed that the N-terminus of Dyn A was inserted in the 
hydrophobic lipid bilayer region, as evident by changes in the NMR, while the C-terminal 
residues were loosely attached to the bicelle surface. In contrast, Dyn B was bound to the 
bilayer but did not insert into the lipid bilayer, and the NMR of the N-terminus did not 
change in the presence of the bicelles.24 Using fluorescence imaging, correlation 
spectroscopy and patch clamp techniques it was recently shown that Dyn A accumulates in 
the plasma membrane of live mammalian cells and causes pore formation, whereas Dyn B 
does not.23 These results from pharmacological and biophysical studies suggest that the non-
opioid cytotoxic effects produced by Dyn A but not by Dyn B may be due in part to either 
transient pore formation and/or membrane perturbations.
While Dyn A and Dyn B have identical N-terminal sequences, their C-terminal sequences 
differ. Hence, differences in their lipid membrane interactions and non-opioid cytotoxic 
effects must be due to differences in their C-terminal sequences.
To date, studies involving structure-activity relationships (SAR) of dynorphins at opioid 
receptors have focused almost exclusively on Dyn A (see refs.25,26 for reviews). These have 
included novel cyclization approaches (N-terminal cyclization27,28 and ring-closing 
metathesis29) and antagonist analogs containing modifications in the N-terminal 
“message”30 sequence,27,31-36 along with some exploration of the SAR of the C-terminal 
sequence in these analogs.37-40 However, there has been minimal SAR evaluation of Dyn B 
analogs. Schiller and coworkers synthesized the Mdp1 (Mdp = (2S)-2-methyl-3-(2,6-
dimethyl-4-hydroxyphenyl)propanoic acid) analog of Dyn B41 as well as of Dyn A-(1-11) 
amide.33 The Dyn A analog dynantin was 180-fold more potent as a KOR antagonist in the 
guinea pig ileum (GPI) assay than the Dyn B analog, indicating the importance of the C-
terminal sequence to the potency of dynantin. This study raises questions concerning the 
contributions of the C-terminal residues in Dyn B vs. Dyn A to the opioid receptor affinities 
and opioid activity of the two peptides.
We hypothesized that unique residue(s) in the C-terminus of Dyn B interact with opioid 
receptors and contribute to the peptide’s opioid activity. To test this hypothesis all of the 
non-glycine residues up through residue 11 of Dyn B amide were substituted with Ala 
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(Figure 2) in order to explore the contributions of these side chains to the pharmacological 
activity profile of Dyn B.
Materials and Methods
Materials
The reagents and solvents used for peptide synthesis were obtained from the sources 
previously reported.40
Peptide synthesis
The peptides were prepared by solid phase peptide synthesis performed on an automated CS 
Bio 336 peptide synthesizer. The peptides were assembled on the PAL-PEG-PS resin (0.19 
mmol/g, 200 mg) using standard Fmoc synthetic strategy. The resin was swollen with 5 mL 
of DMF (2 × 10 min). The Fmoc group on the resin was removed using 20% piperidine in 
DMF (5 mL, 2 × 10 min), and the resin washed with DCM/DMF (1:1, 10 × 30 sec). The 
desired Fmoc-protected amino acids (4 equiv) were coupled to the resin with PyBOP, HOBt 
(4 equiv each) and DIEA (10 equiv) in DMF (2 mL) for 2 h. The side chains of Lys, Gln, 
Arg and Tyr were protected with Boc, trityl (Trt), Pbf and tert-butyl, respectively. The Fmoc 
deprotection of the N-terminal amino acid on the resin was repeated followed by the next 
coupling cycle. The deprotection-coupling cycle was repeated until the desired peptide was 
assembled on the resin.
The peptide resins were treated with Reagent B42 (88% TFA, 5% phenol, 5% water, and 2% 
TIS, 5 mL) for 2 h with occasional shaking. Subsequently, the resins were filtered and the 
TFA was evaporated in vacuo. Water (20 mL) was added to the residues, and the solutions 
lyophilized to give the crude peptides.
Purification and analysis of the peptides
The crude peptides were purified by preparative reversed phase HPLC using an LC-AD 
liquid chromatograph (Shimadzu) equipped with an SPD-10A VP system controller and 
SPD-10A VP UV-Vis detector and a Vydac C18 column (10 μ, 300 Å, 22 mm × 250 mm) 
equipped with a Vydac C18 guard cartridge. For purification, the crude peptides (20–30 mg) 
were dissolved in 75–85% MeOH in water (total volume ~1.5 mL). A linear gradient of 15–
50% aqueous MeCN containing 0.1% TFA over 45 min, at a flow rate of 18 mL/min, was 
used except as noted, and the purifications monitored at 214 nm. Peptide 3 was purified 
using a linear gradient of 30–50% aqueous MeOH containing 0.1% TFA over 40 min. 
Peptide 8 was purified using a linear gradient of 5–40% aqueous MeCN containing 0.1% 
TFA over 70 min with a flow rate of 15 mL/min. The purity of the final peptides was 
verified on a Vydac 218-TP column (5 μ, 300 Å, 4.6 mm × 50 mm) equipped with a Vydac 
guard cartridge on an LC-10AT VP analytical HPLC (Shimadzu) equipped with an 
SCL-10A VP system controller and SPD-10A VP UV-visible detector or on an Agilent 1200 
series liquid chromatograph system equipped with a multiple wavelength UV-visible 
detector. Two systems were used for the analyses: a linear gradient of 5–50% solvent B 
(solvent A = aqueous 0.1% TFA and solvent B = MeCN containing 0.1% TFA) over 45 min, 
at a flow rate of 1 mL/min (system 1), and a linear gradient of 15–0% solvent B (solvent A = 
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aqueous 0.1% TFA and solvent B = MeOH containing 0.1% TFA) over 45 min, also at a 
flow rate of 1.0 mL/min (system 2). The final purity of all peptides by both analytical 
systems was ≥ 98%, except for peptides 3 and 8 (see Table 1). Molecular weights of the 
compounds were determined by ESI-MS using a Waters-time of flight (TOF) mass 
spectrometer (LCT premier, Waters, Milford, MA).
Pharmacological assays
Radioligand binding assays—Radioligand binding assays were performed as 
previously described40,43 using cloned rat KOR and MOR, and mouse DOR stably 
expressed separately on CHO cells and [3H]diprenorphine, [3H]DAMGO ([D-Ala2,N-
MePhe4,Gly-ol]enkephalin) and [3H]DPDPE (cyclo[D-Pen2,D-Pen5]enkephalin), 
respectively, as radioligands. Incubations were carried out in triplicate with varying 
concentrations of peptides (0.1-10,000 nM) for 90 min at RT in the presence of peptidase 
inhibitors and 3 mM Mg2+. Nonspecific binding was determined in the presence of 10 μM 
unlabeled Dyn A-(1-13)NH2, DAMGO and DPDPE for KOR, MOR and DOR, respectively.
[35S]GTPγS assay—The binding of the GTP analog [35S]GTPγS to CHO cell 
membranes expressing cloned KOR was assayed as described previously.40,44 Incubations 
were carried out in triplicate with varying concentrations of peptides (0.1-10,000 nM) for 90 
min at RT in the presence of peptidase inhibitors and 1 μM GDP.
IC50 values and EC50 values from the radioligand binding and [35S]GTPγS assays, 
respectively, were determined by nonlinear regression analysis fit to a logistic equation using 
Prism software (GraphPad Software Co., San Diego, CA). For the radioligand binding 




The peptides were synthesized by the Fmoc (9-fluorenylmethoxycarbonyl) solid phase 
synthetic strategy. The Dyn B amide sequences were assembled on a polyethylene glycol-
polystyrene (PEG-PS) resin containing the PAL [peptide amide linker, 5-(4-Fmoc-
aminomethyl-3,5-dimethoxyphenoxy)valeric acid] linker using 7-benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and 1-hydroxy-7-
benzotriazole (HOBt) as the coupling agents and N,N-diisopropylethylamine (DIEA) as the 
base. The side chains of Lys, Gln, Arg and Tyr were protected with tert-butyloxycarbonyl 
(Boc), trityl (Trt), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) and tert-butyl 
(tBu) groups, respectively. The peptides were assembled using cycles consisting of Fmoc 
deprotection and Fmoc-amino acid coupling. The crude peptides were cleaved from the resin 
using Reagent B42 (trifluoroacetic acid (TFA) in the presence of scavengers).
The peptides were isolated following TFA cleavage and purified according to standard 
procedures (see the Experimental section). The Dyn B amide analogs are hydrophobic and 
required organic solvent for solubilization of the peptides prior to purification by reversed 
phase high performance liquid chromatography (RP-HPLC). MeOH, which is a weaker 
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solvent for RP-HPLC than MeCN, was used to assist in peptide dissolution while 
minimizing the impact on the chromatography.
Pharmacological activity
The opioid receptor binding affinities of the alanine substituted analogs of Dyn B amide 
were determined in Chinese hamster ovary (CHO) cell membranes expressing cloned rat 
MOR and KOR and mouse delta opioid receptors (DOR) (Table 2). As expected, the 
aromatic residues in positions 1 and 4 in the N-terminal sequence of Dyn B amide are 
critical for its opioid receptor affinities. Substitution of Ala in position 1 caused a 141-fold 
decrease, while substitution in position 4 caused a 240-fold decrease in the KOR binding 
affinity compared to Dyn B amide. The Ala1 and Ala4 analogs also exhibited 81- and 129-
fold decreases, respectively, in MOR binding affinity and showed minimal affinity for DOR, 
indicating that these two residues are critical for binding to all three receptors.
The basic residues in the C-terminal sequence all appeared to contribute to the KOR affinity 
of Dyn B amide. Substitutions of Ala for Arg6 and Arg7 caused 7- and 13-fold decreases in 
KOR binding affinity, respectively. Substitution of the C-terminal Lys10 residue by Ala 
caused a 5-fold decrease, suggesting that Lys10 also contributed to KOR binding. In contrast, 
the non-charged residues Leu5, Gln8, Phe9 and Val11 appeared to make minimal 
contributions to KOR affinity; substitution of any of these residues by Ala caused only about 
a 2-fold decrease in KOR affinity.
None of the residues in the C-terminus except Lys10 appeared to significantly contribute to 
the MOR affinity of Dyn B amide. The analogs with Ala substitution in position 6 or 7 
displayed similar (within approximately 2-fold) MOR affinity to Dyn B amide, in contrast to 
the larger decreases observed in the KOR affinities of these analogs. The analogs with Ala 
substitution in place of the nonbasic residues in positions 5, 8, 9 or 11 also displayed similar 
MOR affinities to the parent peptide, with substitution of residue 8 or 9 resulting in the 
highest MOR affinity, 2-fold higher than Dyn B amide. Because of the direction and 
magnitude of the changes of the MOR and KOR affinities, the selectivity of analogs with 
Ala substitution in positions 6 to 9 switched to a small preference for MOR over KOR. 
Interestingly, the analog with substitution of the Lys residue in position 10 showed a 5-fold 
decrease in MOR affinity, suggesting that this residue made a contribution to the MOR 
affinity of Dyn B amide.
Most of the residues in the C-terminus, except those in positions 5 and 10, did not appear to 
contribute to the DOR affinity of Dyn B amide. Substitution of Leu5 and Lys10 by Ala 
decreased DOR affinity by 6- and 3-fold, respectively, while the DOR affinities of the other 
analogs with an Ala substitution in the C-terminus were within 2-fold of the parent peptide. 
The Ala6 analog exhibited the highest DOR affinity of any of the peptides examined, 
although its DOR affinity was within 2-fold that of the parent peptide.
Turcotte et al. performed the Ala scan of Dyn A(1-13)46 (Table 3). Within the N-terminal 
sequence of this peptide Ala1 and Ala4 substitutions caused dramatic decreases in the opioid 
receptor binding affinity, indicating that the Tyr1 and Phe4 residues were critical for the 
opioid receptor affinity of this peptide.46 Among the analogs modified outside of the N-
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terminal tetrapeptide sequence, the Ala5 analog displayed the largest decrease (17-fold) in 
opioid receptor affinity, while the Ala6 and Ala7 analogs showed 7- and 4-fold decreases, 
respectively, in the opioid receptor affinities, suggesting that Leu5, Arg6 and Arg7 in the C-
terminus contributed to opioid receptor interactions. Ala6 and Ala7 analogs of the Dyn A-
(1-11) amide KOR antagonist derivatives arodyn (Ac[Phe1-3,Arg4,D-Ala8]Dyn A-
(1-11)NH2)38 and zyklophin (N-benzyl-Tyr1,cyclo[D-Asp5,Dap8]Dyn A-(1-11)NH240 
showed comparable decreases (3- to 18-fold) in KOR affinity. Ala9 and Ala11 analogs of 
Dyn A-(1–13) also showed small decreases (3-fold) in opioid receptor affinities, suggesting 
that the basic residues in these positions make minor contributions to opioid receptor 
interactions. The agonist potencies of the analogs containing Ala substitutions in positions 1 
and 4 showed a similar trend in the GPI assay as found in the radioligand binding assay.46 
Similarly, among the C-terminal residues positions 5, 6 and 7 contributed the most, while 
residues 9 and 11 also made contributions, to maintaining the agonist potency of Dyn A (1–
13) at opioid receptors in the GPI assay.46
A comparison of the results obtained from the alanine substituted analogs of Dyn A(1–13) 
and Dyn B amide indicates expected similarities between the two peptides, but also some 
subtle differences. As expected, the aromatic residues in positions 1 and 4 of both Dyn A(1–
13) and Dyn B amide are critical for opioid receptor binding. While the Leu residue in 
position 5 is important for opioid receptor binding in the case of Dyn A(1–13), it does not 
make a major contribution to either the KOR or MOR affinity of Dyn B amide, although it 
does appear to make a contribution to the peptide’s DOR affinity. The common basic 
residues in positions 6 and 7 appear to contribute to both the opioid receptor binding of Dyn 
A(1–13) and the KOR binding of Dyn B amide. Among the C-terminal residues of both 
peptides, these basic residues appear to make larger contributions to receptor affinities 
(opioid receptor affinity in the case of Dyn A(1–13) and KOR affinity in the case of Dyn B 
amide) than other residues. The unique basic residues in these peptides (Arg9 and Lys11 in 
Dyn A(1–13) and Lys10 in Dyn B amide) also appear to contribute to the opioid receptor 
affinities of their respective parent peptide. The differences in the relative positions of the 
unique basic residues may be one reason for subtle differences in the pharmacological 
profiles exhibited by the two peptides.
It should be noted that there are several differences in the radioligand binding assays used to 
evaluate the Ala analogs of the two peptides. In the study of Dyn A analogs, the results 
represent a weighted average of the affinities at multiple opioid receptors in rat brain (which 
has relatively low expression of KOR)47 since the radiolabeled opioid agonist used, 
[3H]etorphine, exhibits low selectivity for KOR (KOR/MOR/DOR 1/4/2).48 In the case of 
the Dyn B amide analogs, the opioid affinities were determined using cell membranes 
expressing individual cloned opioid receptors that permitted the different effects of residue 
substitution on KOR affinity vs. MOR and DOR affinity to be assessed. Hence, the 
comparisons of the affinities of the Ala substituted analogs from the two peptides should be 
made with some caution.
The efficacies and potencies of the Ala substituted analogs of Dyn B amide were determined 
at KOR using the [35S]GTPγS assay (Table 4). All of the analogs displayed comparable 
efficacy to the reference agonist Dyn A(1-13)NH2, indicating that none of the residue side 
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chains were required for the KOR efficacy of Dyn B amide. As expected from the KOR 
affinities, the Ala1 and Ala4 analogs exhibited very low potency, and the Ala6 and Ala7 
analogs displayed substantial decreases (13-and 88-fold, respectively) in potency compared 
to Dyn B amide in this assay. The Ala5 analog was 10-fold less potent than the parent 
peptide in this functional assay, even though the KOR affinity was only 2-fold lower than 
Dyn B amide. Similar decreases in potency were observed in the GPI assay for the 
corresponding Dyn A(1–13) analogs.46 In contrast, the Ala10 analog did not exhibit lower 
potency in the KOR [35S]GTPγS assay, in spite of its 5-fold decrease in KOR affinity. Ala 
substitution of the non-basic amino acids in positions 8, 9 and 11 of Dyn B amide also had 
minimal effect on the analogs’ potencies in the [35S]GTPγS assay, as expected based on 
their KOR affinities; similarly, substitution of the non-basic residues in the C-terminus of 
Dyn A(-1-13) also had minimum effects on potency in the GPI assay.46
Conclusions
The results of the alanine scan of Dyn B amide revealed similarities for contributions to 
opioid receptor affinities and agonist potency for residues shared in common with Dyn A(1–
13). As expected, the aromatic residues in positions 1 and 4 in the N-terminal “message” 
sequence30 of both peptides are critical for their opioid receptor binding and agonist 
potency. The basic Arg6 and Arg7 residues in the C-terminal “address” sequence30 also 
contribute substantially to the opioid receptor affinity and agonist potency of Dyn A(1–13) 
and the KOR affinity and agonist potency of Dyn B amide. Interestingly, substitution of 
Leu5 by Ala substantially decreased agonist potency in both Dyn A(1–13) and Dyn B amide, 
although the substitution had a much larger impact on the opioid receptor affinity of the Dyn 
A(1–13) analog than it did on the KOR affinity of the Dyn B amide analog.
The binding affinities at MOR and DOR for the alanine analogs of Dyn B amide indicate 
differences in the contributions of some of these residues to interaction of the parent peptide 
with different opioid receptors. As expected, the N-terminal aromatic residues were 
important for the peptide’s affinity for all three opioid receptors. In contrast, and consistent 
with the “message-address” concept,30 Arg6 and Arg7 contributed to Dyn B amide’s affinity 
for KOR, but not appreciably to MOR or DOR affinity. Interestingly, while substitution of 
Leu5 had a small impact on KOR or MOR affinity (≤2.5-fold decrease relative to Dyn B 
amide), it caused a larger decrease (6-fold) in DOR affinity, enhancing the selectivity of this 
analog for KOR over DOR.
The pharmacological evaluation of the alanine analogs of Dyn B amide also reveal 
contributions of the unique residues in the C-terminal sequence to the pharmacological 
profile of the parent peptide. With the exception of the effect of Lys10 substitution on KOR 
affinity, the impact of Ala substitution of one of these residues on KOR affinity or agonist 
potency was minimal (≤2-fold decrease). Interestingly, the results of Ala substitution for 
Lys10 indicate that this unique C-terminal basic residue enhances affinity for all three opioid 
receptors, although it does not appear to contribute to KOR agonist potency. In Dyn A(1–13) 
the basic residues Arg9 and Lys11 both make significant contributions to agonist potency as 
well as smaller contributions to opioid receptor affinity.46 The different relative positions of 
these basic residues in the two peptides likely contribute to these differences, although there 
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could also be differences in the effects of Arg9 or Lys11 substitution in Dyn A(1–13) on 
interactions with different opioid receptors that could not be determined in the assays 
performed in tissues containing multiple receptors. In contrast to Ala substitution in other 
positions, replacement of either Gln8 or Phe9 of Dyn B amide by Ala slightly increased 
MOR affinity (by 2-fold), resulting in the highest affinities for this receptor and a small 
preference for MOR over KOR. In contrast to substitution of the other unique residues, 
replacement of Val11 by Ala had a minimal effect (≤2-fold difference) on the affinities at any 
of the receptors or potency in the KOR functional assay.
Differences in the sequences of Dyn A and B, however, can result in significant differences 
in the KOR interactions of derivatives of these peptides, as evident from the large differences 
in the relative potencies of the antagonist analogs of these two peptides containing Mdp at 
the N-termini.41 The pharmacological data obtained for the C-terminal Dyn B amide analogs 
support our hypothesis that a unique residue in the C-terminus of Dyn B, Lys10, likely 
interacts with opioid receptors and contributes to the parent peptide’s opioid receptor 
affinities. Other unique residues in the C-terminus of Dyn B amide appear to influence the 
relative affinity of this Dyn for KOR. However, to more fully understand how the C-terminal 
differences in Dyn B affect structure-activity relationships, the preparation and evaluation of 
additional analogs of this peptide are needed; such studies could also result in the 
identification of new useful pharmacological tools.
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Table 1
Analytical data for the Dyn B amide analogs
Compound HPLC system tR (min)a ESI-MS (m/z)b
System 1c System 2d Calculated Observed
1 19.1 29.1 739.4 739.4
2 20.7 24.6 747.4 747.4
3 21.7e 23.9f 764.4 764.4
4 22.2 34.5 742.9 742.9
5 23.8 33.3 742.9 742.9
6 29.9 39.8 756.9 756.9
7 16.6 23.2 747.4 747.4
8 20.3g 31.1 756.9 756.9
9 20.1 30.0 771.4 771.4
Dyn B amide 18.6 31.9 785.4 785.4
a




Aqueous MeCN containing 0.1% TFA.
d




Peptide 3: tR = 18.4 min and 96.2% purity using a gradient of 25–45% aqueous MeOH containing 0.1% TFA over 40 min.
g
95.5% purity
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Table 2
Opioid binding affinities of Dyn B amide alanine analogs.
Tyr1-Gly-Gly-Phe4-Leu5-Arg6-Arg7-Gln8-Phe9-Lys10-Val11-Val-Thr-NH2
Compound Ki (nM ± SEM)a
KOR MOR DOR KOR/MOR/DOR
N-Terminal alanine substituted analogs
 1 [Ala1] 886 ± 123 651 ± 70 >10,000 1/0.7/>11
 2 [Ala4] 1510 ± 221 1040 ± 100 >10,000 1/0.7/>6
C-Terminal alanine substituted analogs
 3 [Ala5] 12.1 ± 5.2 20.3 ± 3.1 265 ± 43 1/2/22
 4 [Ala6] 43.1 ± 2.8 14.1 ± 3.0 25.7 ± 1.6 1/0.3/0.6
 5 [Ala7] 82.4 ± 9.3 16.7 ± 5.1 67.5 ± 8.3 1/0.2/0.8
 6 [Ala8] 13.0 ± 0.96 4.32 ± 0.10 54.0 ± 6.9 1/0.3/4
 7 [Ala9] 11.3 ± 1.7 3.76 ± 0.22 42.1 ± 2.5 1/0.3/4
 8 [Ala10] 31.6 ± 6.0 40.5 ± 3.9 119 ± 16 1/0.8/4
 9 [Ala11] 12.4 ± 1.6 7.45 ± 2.69 58.8 ± 3.4 1/0.6/5
Dyn B amide 6.30 ± 1.68 8.05 ± 2.87 43.2 ± 1.6 1/1.3/7
a
Values are mean ± SEM for n ≥ 3.
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Table 3
Opioid receptor affinities and agonist potencies of alanine analogs of Dyn A(1–13)28
Tyr1-Gly2-Gly3-Phe4-Leu5-Arg6-Arg7-Ile8-Arg9-Pro10-Lys11-Leu-Lys
Peptide Affinity Agonist potency
IC50 (nM)a Fold decreaseb IC50 (nM)c Fold decreaseb
[Ala1] Dyn A(1-13) 1400 ± 210 519 750 ± 30 1070
[Ala2]- ″ 13.5 ± 0.4 5 104 ± 32 149
[Ala3]- ″ 21.5 ± 3.7 8 2.0 ± 0.3 3
[Ala4]- ″ 750 ± 35 278 700 ± 20 1000
[Ala5]- ″ 45.0 ± 1.1 17 14 ± 4 20
[Ala6]- ″ 19.2 ± 0.8 7 23 ± 6 33
[Ala7]- ″ 10.0 ± 1.2 4 19 ± 5 27
[Ala8]- ″ 0.3 ± 0.0 – 1.4 ± 0.1 2
[Ala9]- ″ 7.4 ± 0.8 3 5.5 ± 0.8 8
[Ala10]- ″ 3.8 ± 0.5 1.5 3.3 ± 0.7 5
[Ala11]- ″ 8.7 ± 0.9 3 7.6 ± 0.4 11
Dyn A(1-13) 2.7 ± 0.3 – 0.7 ± 0.1 –
a
IC50 obtained from radioligand binding assays using[3H]etorphine in rat brain homogenates.
b
Compared to Dyn A(1-13).
c
IC50 obtained from the GPI assay.
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Table 4
Potencies and efficacies of the Dyn B amide alanine analogs at KOR in the GTPγS assay
Peptide EC50 (nM ± SEM)a,b
N-Terminal alanine substituted analogs
1 [Ala1] 2650 ± 890
2 [Ala4] 1180 ± 330
C-Terminal alanine substituted analogs
3 [Ala5] 109 ± 34
4 [Ala6] 116 ± 21
5 [Ala7] 802 ± 290
6 [Ala8] 20.2 ± 10.8
7 [Ala9] 14.8 ± 2.6
8 [Ala10] 6.36 ± 1.70
9 [Ala11] 8.79 ± 2.20
Dyn B NH2 9.14 ± 1.96
a
Values are for n ≥ 2.
b
All analogs exhibited ≥90% efficacy as compared to Dyn A(1-13)NH2 (efficacy = 100%) except for Ala10 (86 ± 3% efficacy).
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